GEN Exclusives

More »

GEN News Highlights

More »
Nov 3, 2006

Dutch Government Invests EUR 18M in TB Vaccine Development

  • The Dutch Ministry of Foreign Affairs  made a EUR 18.4-million, four-year investment in Aeras Global TB Vaccine Foundation, a product development partnership that is collaborating with Crucell, KNCV Tuberculosis Foundation, Netherlands Cancer Institute, and other Dutch organizations to develop new TB vaccines.

    In Aeras’ prime-boost strategy, an improved TB vaccine, the prime, will be given initially, and another type of vaccine, the boost, will be given at a specified period of time after the prime vaccination. One of the foundation’s products, Aeras 402/Crucell Adenovirus35 TB vaccine, recently entered clinical trials.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »